517 related articles for article (PubMed ID: 28432473)
1. Vasopressin and Vasopressin Antagonists in Heart Failure.
Vishram-Nielsen JK; Gustafsson F
Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
Urbach J; Goldsmith SR
Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
4. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
Lin TE; Adams KF; Patterson JH
Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin receptor antagonists in heart failure.
Hobbs RE; Tang WH
Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
[TBL] [Abstract][Full Text] [Related]
6. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
[TBL] [Abstract][Full Text] [Related]
7. Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?
Valania G; Singh M; Slawsky MT
Curr Heart Fail Rep; 2011 Sep; 8(3):198-205. PubMed ID: 21046492
[TBL] [Abstract][Full Text] [Related]
8. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
9. Vasopressin antagonists: role in the management of hyponatremia.
Yeates KE; Morton AR
Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
[TBL] [Abstract][Full Text] [Related]
10. Vasopressin antagonists in heart failure.
Golestaneh L; Talreja A; Le Jemtel TH
Curr Heart Fail Rep; 2004 Dec; 1(4):190-6. PubMed ID: 16036044
[TBL] [Abstract][Full Text] [Related]
11. Vasopressin-receptor antagonists in heart failure.
Schweiger TA; Zdanowicz MM
Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
[TBL] [Abstract][Full Text] [Related]
12. [Vasopressin receptor antagonists and heart failure].
Haass M
Ther Umsch; 2009 Nov; 66(11):735-40. PubMed ID: 19885790
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
14. AVP receptor antagonists in patients with CHF.
Kumar SK; Mather PJ
Heart Fail Rev; 2009 Jun; 14(2):83-6. PubMed ID: 18766439
[TBL] [Abstract][Full Text] [Related]
15. Hyponatremia in heart failure: the role of arginine vasopressin and diuretics.
Rosner MH
Cardiovasc Drugs Ther; 2009 Aug; 23(4):307-15. PubMed ID: 19554441
[TBL] [Abstract][Full Text] [Related]
16. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
Mondritzki T; Mai TA; Vogel J; Pook E; Wasnaire P; Schmeck C; Hüser J; Dinh W; Truebel H; Kolkhof P
Eur J Heart Fail; 2021 May; 23(5):743-750. PubMed ID: 32946151
[TBL] [Abstract][Full Text] [Related]
17. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
Imamura T; Kinugawa K
Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
[TBL] [Abstract][Full Text] [Related]
18. V2 receptor antagonism with tolvaptan in heart failure.
Costello-Boerrigter LC; Boerrigter G; Burnett JC
Expert Opin Investig Drugs; 2007 Oct; 16(10):1639-47. PubMed ID: 17922627
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
Ferrer E
Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590
[TBL] [Abstract][Full Text] [Related]
20. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
